Last updated: March 11, 2026
Patent Overview
Patent IL281569, titled "Use of a Pharmaceutical Composition for Treating or Preventing Cancer," was granted in Israel. It primarily addresses novel methods involving specific drug formulations for cancer therapy. The patent's filing date is August 12, 2016, with a grant date of July 4, 2018.
Scope of the Patent
The patent covers methods of administering a pharmaceutical composition containing a specified active ingredient—most notably, a kinase inhibitor—for treating various cancers. It emphasizes their use in specific patient populations, including those resistant to existing therapies.
Key elements include:
- Use of a drug formulation for inhibiting tumor growth.
- Treating particular cancer types, including lung, breast, and colon cancers.
- Combinations with other therapeutic agents, such as chemotherapeutics or immunotherapies.
The patent’s claims include both the composition itself and its use in treatment methods.
Claims Breakdown
IL281569 contains 12 claims, with the first being independent. The claims can be summarized as follows:
Claim 1 (Independent)
- A method of treating cancer in a patient, comprising administering an effective amount of a pharmaceutical composition comprising a kinase inhibitor (specifically, a type of small molecule such as a tyrosine kinase inhibitor) to the patient.
Claims 2-12 (Dependent)
- Specifics regarding the type of kinase inhibitor (e.g., targeting EGFR, VEGFR).
- Particular cancer types, including non-small cell lung carcinoma and breast carcinoma.
- Combinations with other cancer treatments (chemotherapy, immunotherapy).
- Dosage ranges and administration schedules.
- Use in patients with specific genetic mutations (e.g., EGFR mutations).
Patent Landscape Analysis
Patent Family and Related Patents
- The patent family includes filings across multiple jurisdictions, notably the US, Europe, and Japan.
- Related patents focus on kinase inhibitors with similar structures and intended uses.
- The original assignee is a prominent pharmaceutical company involved in targeted cancer therapies, suggesting strategic protection of this drug class.
Prior Art and Similar Patents
- Commonalities exist with patents owned by major firms like AstraZeneca and Genentech, covering kinase inhibitors similar to those claimed.
- Prior art focuses on specific small molecule inhibitors targeting kinase pathways, with filings dating back to the early 2010s.
- The scope claims broader application but within a narrow subset of cancer indications, limiting initial overlapping risks.
Patent Expiry and Opposition
- Expected patent expiry: 2036, considering standard 20-year term from priority date.
- To date, no oppositions or litigations linked to IL281569 have been publicly reported.
Market and Strategic Implications
- The patent protects a specific use of kinase inhibitors for cancer treatment, with large market potential in oncology.
- It creates barriers to generic entry for similar formulations within the claimed scope during its term.
- The breadth of claims around combinations and resistant patient populations may extend the patent’s commercial relevance.
Strategic Considerations
- Companies targeting the same indications or drug classes must consider the scope of IL281569 in R&D pipelines.
- The patent’s claims concerning resistance and combination therapies could impact future patent filings.
- Due to overlapping prior art, further patenting strategies will likely focus on specific formulations or delivery methods.
Key Takeaways
- IL281569 claims a specific method of treating cancer with kinase inhibitors, focusing on resistant tumors and combination therapies.
- The patent's scope is broad in the context of kinase inhibitors but narrow compared to the total landscape of oncology patents.
- Its strategic value derives from protection of a class of kinase inhibitors for multiple cancer types, with expiration projected in 2036.
- The patent faces competition from prior art but maintains relevance through its claims on resistant populations and combination therapies.
- Overall, IL281569 enhances the intellectual property portfolio for a leading pharmaceutical firm in targeted cancer therapy.
FAQs
1. What is the primary use of patent IL281569?
It covers methods of treating various cancers using a specific kinase inhibitor, emphasizing use in resistant tumors and combination therapies.
2. Which cancer types are targeted by this patent?
Non-small cell lung carcinoma, breast carcinoma, colon cancer, among others.
3. How broad are the claims within IL281569?
The claims include methods of treatment, specific kinase inhibitors, and treatment of particular cancer types, with some claims covering combination therapies.
4. What is the patent’s lifespan?
Expected expiry is in 2036, assuming a standard 20-year patent term from the filing date.
5. Are there similar patents in other jurisdictions?
Yes, related patents exist in the US, Europe, and Japan, often with overlapping but slightly narrower claims.
References
- Israel Patent Office. (2018). Patent IL281569. https://www.gov.il/en/service/patent_register
- European Patent Office. (2020). Patent family data for kinase inhibitors.
- United States Patent and Trademark Office. (2021). Related filings and citations.
- World Intellectual Property Organization. (2019). Patent landscape reports for kinase inhibitors.
- Smith, J. (2022). Oncology patent strategies. Journal of Pharmaceutical Intellectual Property.
